USPTO serial 86605899
MEDIGENE IMMUNOTHERAPIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 13, 2016
- Examiner
- LEASER, ANDREW C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MEDIGENE IMMUNOTHERAPIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Planegg/Martinsried, DE
Planegg/Martinsried, DE
Planegg/Martinsried, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leonard P. Linardakis
Leonard P. Linardakis Moser Taboada1030 Broad Street - Suite 203Shrewsbury, NJ 07702UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for humans and animals for the treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, vaccines, medicated serums for treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, diagnostic and drug testing kits comprised of medical reagents and assays for testing of bodily fluids for use in disease detection, namely, tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, all prepared by means of molecular biology, genetic engineering or biotechnological methods; substances for medical diagnosis purposes, namely, proteins, nucleic acids, cell products, protein conjugates, peptides, enzymes and enzyme preparations, particularly antibodies and T cell proteins; T cells, dendritic cells, and other cells of the immune system, viruses, and virus-like particles, all for medical purposes; liposomes for medical purposes; plant extracts for medical purposes; low molecular active ingredients, namely, medicines for the treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, vaccines, adjuvants, serums for treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, diagnostic and drug testing kits comprised of medical reagents and assays that test for the presence of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases and immune therapy | SECTION 8 - CANCELLED | — |
| 042 | Services of a molecular biology or biotechnology laboratory, particularly research and development work in the field of human medical and veterinary medical diagnosis and therapy by means of molecular biology, genetic engineering or biotechnological methods as well as in the field of screening for pharmaceutically active compounds; design and development of test methods and test kits in the field of biotechnology and medicine | SECTION 8 - CANCELLED | — |
| 044 | Medical analyses and medical consultancy in the context of the treatment of single persons, particularly in the field of tumor precursors, benign and malignant tumor diseases, autoimmune diseases and immunotherapy | SECTION 8 - CANCELLED | — |
| 045 | Licensing of intellectual property, including trademarks and patents in the field of biotechnology, pharmacy, and medicine | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named MEDIGENE IMMUNOTHERAPIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 24, 2023 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 13, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 13, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 28, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 28, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 8, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 23, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 13, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 6, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 6, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 6, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 17, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 21, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 21, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2015 | ALIE | ASSIGNED TO LIE | — |
| Sep 23, 2015 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 7, 2015 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 7, 2015 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 7, 2015 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 7, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 7, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 31, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2015 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| May 1, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 25, 2015 | NWAP | NEW APPLICATION ENTERED | — |